Form 4: Serina Therapeutics Director Acquires Stock Options

Serina Therapeutics Director Jay Venkatesan was granted 10,000 stock options with an exercise price of $3.91, vesting over one year.

Summary

• Jay Venkatesan, a Director of Serina Therapeutics, Inc. (SER), acquired 10,000 stock options.
• The transaction date for the option grant was November 7, 2025.
• Each stock option has an exercise price of $3.91.
• The options will vest on the earlier of the day before the next Annual Meeting or the one-year anniversary of the grant date, subject to continued service.
• The expiration date for these stock options is November 7, 2035.
• Following this transaction, Jay Venkatesan beneficially owns 10,000 derivative securities directly.

Sentiment

Score: 6

Explanation: The grant of stock options to a director is a standard compensation practice that aligns the director's interests with those of shareholders, which is generally viewed positively. However, it does not provide new operational or financial performance information, hence a neutral-to-slightly positive score.

Positives

• The grant of stock options aligns the director's financial interests with those of the shareholders, incentivizing long-term performance.
• This is a standard compensation practice for directors, indicating routine corporate governance.

Future Outlook

The stock options are subject to vesting conditions, requiring Jay Venkatesan's continued service to Serina Therapeutics through the applicable vesting dates, which will be the earlier of the day before the next Annual Meeting or the one-year anniversary of the grant date.

Industry Context

The grant of stock options to a director is a common practice in the biotechnology and pharmaceutical industries, as well as other sectors, to incentivize leadership and align their long-term interests with shareholder value creation. This type of compensation is a standard component of executive and director remuneration packages.

Comparison to Industry Standards

• The grant of stock options as part of director compensation is a widely accepted industry standard across publicly traded companies, particularly in growth-oriented sectors like biotechnology.
• The vesting schedule, tied to continued service, is typical for equity awards designed to retain key personnel and ensure commitment.

Stakeholder Impact

• Shareholders: The grant of options aims to align the director's interests with long-term shareholder value, potentially leading to more focused strategic decisions.
• Employees: No direct impact mentioned, but such compensation practices can set precedents for broader equity incentive programs.

Next Steps

• The stock options will vest on the earlier of the day before the next Annual Meeting or the one-year anniversary of the grant date (November 7, 2026), contingent on continued service.

Key Dates

Keywords

Serina Therapeutics, SER, Stock Options, Insider Transaction, Form 4, Director Compensation, Equity Grant, Vesting